Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

News SummaryMost relevantAll newsSector newsTweets

Celgene pens pact to join Bristol-Myers, Pfizer in R&D race

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 12:18pm CEST

Celgene has secured an option on two preclinical assets in development at Nimbus Therapeutics. The deal gives Celgene a chance to move into the slipstreams of Bristol-Myers Squibb and Pfizer in the race to bring a TYK2 inhibitor to market.

TYK2 has attracted the interest of multiple major research groups on the strength of its role in the inflammatory response. Bristol-Myers has advanced its shot at the target, BMS-986165, into phase 2 trials in lupus and psoriasis. Pfizer is testing its TYK2-JAK1 kinase inhibitor, PF-06700841, in three phase 2 trials, which are enrolling patients with alopecia areata, ulcerative colitis and psoriasis.

Nimbus program has ceded a sizable head start to these drugs, but Celgene has seen enough in the preclinical data to suggest it can come from behind. That confidence is based, in part, on evidence Nimbus inhibitors are particularly selective for TYK2, enabling them to hit the target but not its JAK siblings.

The importance of TYK2 means there are plenty of opportunities to go around, too. A TYK2 inhibitor could treat autoimmune conditions including rheumatoid arthritis, Crohns disease and multiple sclerosis, as well as the indications being pursued in the clinic by Bristol-Myers and Pfizer.

We are excited about the potential of the Nimbus immunology targets, which are based on compelling human genetic data, Celgene R&D VP Robert Plenge, M.D., Ph.D., said in a statement. Moreover, Nimbus robust in silico-based approach is very promising.

That prompted the prolific dealmaker to put together an agreement that gives it an option to buy the program for an as-yet-undisclosed upfront payment and downstream milestones. The release of clinical trial data will trigger the buy-in decision on the TYK2 program and other assets covered by the deal. Nimbus is in charge of advancing the assets until Celgene exercises its option.

The second asset covered by the agreement is designed to block STING from activating the innate immune system in interferonopathies such as lupus. Nimbus agreement leaves it free to develop a small molecule agonist program with applications in immuno-oncology.

That immuno-oncology program is the only publicly disclosed part of Nimbus pipeline that is not yet the subject of a deal. Gilead and Genentech have already picked off other parts of the pipeline through an acquisition and licensing deal, respectively.

(c) 2017 AIN. All Rights Reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
10/17 IBD Announces First Annual Biotech Innovator Awards
10/17 CELGENE : More positive ozanimod data bolsters the drug`s profile
10/16 CELGENE CORPORATION : Today's Research Reports on Stocks to Watch: Celgene Corpo..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn's Disease and U..
10/16 CELGENE : Results from Phase 2 Studies of Oral Ozanimod in Crohn’s Disease..
10/13 CELGENE : Sutro Marks Two Drug Development Milestones
10/12 CELGENE : Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology A..
10/12 EVOTEC : achieves first milestone in neurodegeneration alliance with Celgene
10/07 BRISTOL MYERS SQUIBB : Industry Leaders Gather at Medidata NEXT Global 2017 to D..
10/05 Celgene pens pact to join Bristol-Myers, Pfizer in R&D race
More news
News from SeekingAlpha
10/17 YOUR DAILY PHARMA SCOOP : Everybody's Gilead Problem, Halozyme's Further Progres..
10/17 Premarket analyst action - healthcare
10/16 President Trump at it again with comments on "out of control" drug prices
10/14 Stocks to watch next week
10/12 Acceleron's Unique Pipeline Looks Undervalued
Financials ($)
Sales 2017 13 248 M
EBIT 2017 7 532 M
Net income 2017 4 348 M
Debt 2017 3 768 M
Yield 2017 -
P/E ratio 2017 24,24
P/E ratio 2018 18,71
EV / Sales 2017 8,36x
EV / Sales 2018 6,84x
Capitalization 107 B
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 155 $
Spread / Average Target 13%
EPS Revisions
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON18.42%365 346
NOVARTIS13.23%226 956
ROCHE HOLDING LTD.5.20%215 359
PFIZER11.88%214 265